Genetic factors (VKORC1, CYP2C9, EPHX1, and CYP4F2) are predictor variables for warfarin response in very elderly, frail inpatients (Q43268895)

17 November 2017

Genetic factors (VKORC1, CYP2C9, EPHX1, and CYP4F2) are predictor variables for warfarin response in very elderly, frail inpatients (English)

1 reference

17 November 2017

1 reference

12

1 reference

17 November 2017

E Pautas

1

1 reference

17 November 2017

C Moreau

2

1 reference

17 November 2017

I Gouin-Thibault

3

1 reference

17 November 2017

J-L Golmard

4

1 reference

17 November 2017

I Mahé

5

1 reference

17 November 2017

C Legendre

6

1 reference

17 November 2017

E Taillandier-Hériche

7

1 reference

17 November 2017

B Durand-Gasselin

8

1 reference

17 November 2017

A-M Houllier

9

1 reference

17 November 2017

P Verrier

10

1 reference

17 November 2017

P Beaune

11

1 reference

17 November 2017

V Siguret

13

1 reference

17 November 2017

language of work or name

English

0 references

publication date

30 September 2009

1 reference

Clinical Pharmacology & Therapeutics

17 November 2017

1 reference

17 November 2017

87

1 reference

17 November 2017

1

1 reference

17 November 2017

57-64

1 reference

https://scigraph.springernature.com/pub.10.1038/clpt.2009.178

17 November 2017

0 references

cites work

Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.178

Age and the risk of warfarin-associated hemorrhage: the anticoagulation and risk factors in atrial fibrillation study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.178

Major hemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.178

Pharmacogenetics of warfarin elimination and its clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.178

Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.178

CYP2C9 genotypes and dose requirements during the induction phase of oral anticoagulant therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.178

Equal proportion of adult male and female homozygous for the 677C ? T mutation in the methylenetetrahydrofolate reductase polymorphism

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.178

A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.178

Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.178

Association of warfarin dose with genes involved in its action and metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.178

CYP4F2 genetic variant alters required warfarin dose

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.178

The largest prospective warfarin-treated cohort supports genetic forecasting

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.178

The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.178

Genotypes of the cytochrome p450 isoform, CYP2C9, and the vitamin K epoxide reductase complex subunit 1 conjointly determine stable warfarin dose: a prospective study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.178

Randomized trial of genotype-guided versus standard warfarin dosing in patients initiating oral anticoagulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.178

Genetic-based dosing in orthopedic patients beginning warfarin therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.178

Dosing algorithms to predict warfarin maintenance dose in Caucasians and African Americans

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.178

Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.178

Genetic determinants of response to warfarin during initial anticoagulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.178

Relative contribution of CYP2C9 and VKORC1 genotypes and early INR response to the prediction of warfarin sensitivity during initiation of therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.178

Initiation of warfarin therapy in elderly medical inpatients: a safe and accurate regimen.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.178

Common VKORC1 and GGCX polymorphisms associated with warfarin dose

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.178

CYP4F2 is a vitamin K1 oxidase: An explanation for altered warfarin dose in carriers of the V433M variant

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.178

Estimation of the warfarin dose with clinical and pharmacogenetic data

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.178

Estimation of height and body mass index from demi-span in elderly individuals.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.178

Genetic mechanisms for hypersensitivity and resistance to the anticoagulant Warfarin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.178

Epoxide hydrolases: mechanisms, inhibitor designs, and biological roles

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.178

A "silent" polymorphism in the MDR1 gene changes substrate specificity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.178

A genome-wide scan for common genetic variants with a large influence on warfarin maintenance dose

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.178

A genome-wide association study confirms VKORC1, CYP2C9, and CYP4F2 as principal genetic determinants of warfarin dose

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.178

Pharmacogenetic relevance of CYP4F2 V433M polymorphism on acenocoumarol therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.178

Warfarin maintenance dosing patterns in clinical practice: implications for safer anticoagulation in the elderly population

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.178

Combination of phenotype assessments and CYP2C9-VKORC1 polymorphisms in the determination of warfarin dose requirements in heavily medicated patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.178

Pharmacoepigenetics: its role in interindividual differences in drug response

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.178

Systematic overview of warfarin and its drug and food interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.178

Validation of the Cumulative Illness Rating Scale in a geriatric residential population

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.178

Cytochrome P450 2C9 (CYP2C9) and vitamin K epoxide reductase (VKORC1) genotypes as determinants of acenocoumarol sensitivity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.178

Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.178

7 January 2021

An analysis of the relative effects of VKORC1 and CYP2C9 variants on anticoagulation related outcomes in warfarin-treated patients.

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.178

7 January 2021

The elderly--a challenge for appropriate drug treatment

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.178

7 January 2021

Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.178

7 January 2021

No clear link between VKORC1 genetic polymorphism and the risk of venous thrombosis or peripheral arterial disease

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.178

7 January 2021

Identifiers

DOI

10.1038/CLPT.2009.178

1 reference

Dimensions Publication ID

17 November 2017

0 references

1 reference